Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37190294/
Triple-negative breast carcinoma (TNBC) is one of the most aggressive types of solid-organ cancers. While immune checkpoint blockade (ICB) therapy has significantly improved outcomes in certain types of solid-organ cancers,...
Conclusions/Relevance: We developed a potentially curative immunotherapeutic regimen consisting of HMGN1, FSL-1, R848, plus a checkpoint inhibitor for TNBC, which does not rely on the administration of chemotherapy, radiation, or exogenous tumor-associated antigen(s).
Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors
Source : https://www.mdpi.com/2072-6694/15/7/2000
Few data are available about the immune response to mRNA SARS-CoV-2 vaccines in patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). We conducted a prospective, single-center study of...
Conclusions: In conclusion, patients treated with CDK4/6i showed a robust humoral response, but a blunted trend of T-cell response in comparison with a cohort of healthy volunteers, suggesting a trend of reduced adaptative immune response in this group. Moreover, a higher risk of infection was observed during follow-up in those patients with...
Copy number aberrations in ctDNA enables prognosis prediction and molecular characterization of breast cancer
You do not currently have access to this article. Don't already have a personal account? Register Copy number aberrations in ctDNA enables prognosis prediction and molecular characterization of breast cancer...
Conclusions: These results demonstrate LP-WGS ctDNA CNA analysis as an essential tool for prognosis prediction and molecular profiling. Particularly, ctDNA CNA burden can serve as a useful determinant for escalating or de-escalating (neo)adjuvant strategy in TNBC patients.
Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37166793/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions and Relevance: In this cohort study of patients with HR-positive mBC treated with TT plus ET, low ERBB2 expression did not have a significant association with prognosis.
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37146620/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Relevance: The monarchE investigators respectfully disagree with the comments of Tomer Meirson and colleagues in their Essay in The Lancet Oncology regarding the role of adjuvant abemaciclib in patients with early breast cancer. monarchE was a large, global, randomised study conducted in patients with high-risk, hormone...